Axiom: Transforming Drug Development with AI and Amplify Partners' Investment

Amplify Partners has announced its seed investment in Axiom, a company focused on transforming drug toxicity testing using AI and computational models. Drug toxicity, particularly liver toxicity, is a massive issue in pharmaceutical development, leading to billions in losses due to drug failures and market withdrawals. Axiom aims to address this by harnessing an extensive dataset dedicated to chemical toxicity in human cells and leveraging advanced AI models to predict liver toxicity more accurately than traditional animal testing. Founded by Brandon White and Alex Beatson, Axiom has developed a proprietary platform that screens chemical compounds against live human hepatocytes at scale, capturing a multitude of data points. With over 115,000 unique small molecules and 394+ million cells analyzed, Axiom’s AI models promise a cost-effective and efficient alternative for drug safety testing. The recent funding totaling $15 million, including investments from Amplify and Dimension Capital, positions Axiom to revolutionize the toxicology field and potentially extend its predictive models to other vital organs. The industry need for such innovative solutions is pressing, especially with the FDA's recent mandate to reduce animal testing and an increased emphasis on AI tools.